Navigation Links
Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology
Date:9/23/2008

First Such Board on the Market, Stantum's SMK Series Will Let Vendors Cost-Effectively Develop Their Own Resistive Multi-Touch Applications

SAN DIEGO, Sept. 23 /PRNewswire/ -- Stantum Technologies (http://www.stantum.com), a pioneer developer of multi-touch sensing technology, today introduced a demo, evaluation and development board based on its patented PMatrix(TM) resistive multi-touch technology, which lets users simultaneously move an unlimited number of fingers, nails or utensils (such as styli) on a screen.

The first such board on the market, the new SMK series enables vendors and OEMs to evaluate the performance of Stantum's technology and begin developing their own resistive multi-touch applications, thanks to a user-friendly interface compatible with Windows, MAC OS and Linux.

"Stantum is demonstrating that -- contrary to widespread misbelief -- multi-touch is possible with a cost-effective resistive touch-panel platform," said Chris Crotty, director of small and medium displays research at DisplaySearch, a leading provider of information, consulting and conferences on the display supply chain and display-related industries. "With this groundbreaking announcement, Stantum is combining the best of both worlds by offering the features of projected capacitive multi-touch with the lower cost and widespread availability of resistive touch technology."

Added Guillaume Largillier, Stantum's co-founder and CEO: "Our SMK series is the smart multi-touch development kit that the consumer electronics and other industries have long anticipated. It gives manufacturers developing their hardware and applications a great opportunity to assess the huge advantages that multi-touch capability can offer, especially when it uses resistive technology."

SMK boards come with either a 2.5- or 3.5-inch touch-panel sensor; a multi-touch controller; Stantum's Lemurofon software, for demonstr
'/>"/>

SOURCE Stantum
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Positron emission tomography superior to standard evaluation tools in measuring treatment response
2. Gender, coupled with diabetes, affects vascular disease development
3. New target for anti-flu drug development
4. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
5. KAUST and American University in Cairo to collaborate on research and academic development
6. Old developmental pathways spawn revolutionary evolutionary changes
7. NIST announces 56 new awards for innovative technology research and development
8. Progress Against Malaria: Developments on the Horizon
9. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
10. Biopharmaceutical infrastructure key to lower drug development costs
11. Study identifies pathway required for normal reproductive development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... infectious diseases are urgently needed in resource-limited countries. ... Academy of Microbiology colloquium, "Bringing the Lab to ... Settings," describes the challenges inherent in bringing new ... the world where they are needed most. Point-of-care ...
... team of UC Davis investigators has found that a genetic ... prostate cancer. The mutation of the so-called p53 (or Tp53) ... now has never been shown to act as an initiating ... treating the disease. The study was published online ...
... one of the few probiotics with medical food designation for ... of more than 80 studies that have demonstrated its use ... ileal pouch. Ulcerative colitis patients, in particular, have been shown ... drug regimen. One particular study shows that the combination of ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... October 22, 2014 WriteResult, LLC ... – has been working with a team of researchers ... Haven Farms Community Farming Collaborative to provide electronic questionnaire ... The study, which started in May, aims to ... provides participants weekly exposure to and participation in urban ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Medarex, Inc. (Nasdaq: MEDX ) announced today ... J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 ... will be webcast live and will be available in the ... . An archived edition of the presentation will be available ...
... PCYC ) today announced that in ... Associates ("RWD") made an unsecured loan to,Pharmacyclics, Inc. ... $5,000,000. As of,December 31, 2008, the company,s ... the $5,000,000 in loan proceeds. RWD,is controlled ...
... Jan. 6 Omeros Corporation today announced that The ... grant against milestones to support the Company,s collaboration with ... a new target for the treatment of Parkinson,s disease. ... disease, Omeros is the first to link its novel ...
Cached Biology Technology:Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Pharmacyclics Secures $5.0 Million in Debt Financing 2Pharmacyclics Secures $5.0 Million in Debt Financing 3Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 3
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Mouse Cell Line Slides...
Biology Products: